Business Description
Spruce Biosciences Inc
NAICS : 541714
SIC : 2833
ISIN : US85209E2081
Share Class Description:
SPRB: Ordinary SharesTotal Employee Number:
8Description
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.59 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -0.2 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 29.6 | |||||
3-Year EPS without NRI Growth Rate | 32 | |||||
3-Year FCF Growth Rate | 31.1 | |||||
3-Year Book Growth Rate | -47.8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 40.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.78 | |||||
9-Day RSI | 50.34 | |||||
14-Day RSI | 49.99 | |||||
3-1 Month Momentum % | -30.07 | |||||
6-1 Month Momentum % | -45.64 | |||||
12-1 Month Momentum % | 801.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.67 | |||||
Quick Ratio | 4.67 | |||||
Cash Ratio | 4.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -63.3 | |||||
Shareholder Yield % | 0.16 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -167.45 | |||||
ROA % | -104.49 | |||||
ROIC % | -1041.4 | |||||
3-Year ROIIC % | -516.05 | |||||
ROC (Joel Greenblatt) % | -4970.42 | |||||
ROCE % | -148.29 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.08 | |||||
Price-to-Tangible-Book | 2.08 | |||||
EV-to-EBIT | -2.68 | |||||
EV-to-EBITDA | -2.7 | |||||
EV-to-Forward-Revenue | 13.17 | |||||
EV-to-FCF | -3.33 | |||||
Price-to-GF-Value | 12.87 | |||||
| Price-to-Net-Current-Asset-Value | 2.15 | |||||
| Price-to-Net-Cash | 2.21 | |||||
Earnings Yield (Greenblatt) % | -37.31 | |||||
FCF Yield % | -20.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SPRB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Spruce Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -37.608 | ||
| Beta | 3.9181 | ||
| 3-Year Sharpe Ratio | 0.51 | ||
| 3-Year Sortino Ratio | 4.14 | ||
| Volatility % | 1132.51 | ||
| 14-Day RSI | 49.99 | ||
| 14-Day ATR ($) | 3.722122 | ||
| 20-Day SMA ($) | 51.48625 | ||
| 12-1 Month Momentum % | 801.69 | ||
| 52-Week Range ($) | 4.962 - 240 | ||
| Shares Outstanding (Mil) | 2.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Spruce Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Spruce Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 128 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 40 days | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-04 11:05 | 49.05 (+2.00%) | ||
| General meeting for 2026 | 2026-05-21 10:00 | 51.52 (+3.26%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 56.67 (+1.64%) | ||
| The Citizens Life Sciences Conference | 2026-03-10 12:30 | 62.11 (+18.37%) | ||
| Leerink Global Healthcare Conference | 2026-03-09 11:20 | 55.87 (+7.17%) | ||
| Annual report for 2025 | 2026-03-09 | 55.87 (+7.17%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-09 | 55.87 (+7.17%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 15:20 | 59.41 (+9.98%) |
Show
Entries
Spruce Biosciences Inc Frequently Asked Questions
What is Spruce Biosciences Inc(SPRB)'s stock price today?
The current price of SPRB is $52.51. The 52 week high of SPRB is $240.00 and 52 week low is $4.96.
When is next earnings date of Spruce Biosciences Inc(SPRB)?
The next earnings date of Spruce Biosciences Inc(SPRB) is 2026-08-14 Est..
Does Spruce Biosciences Inc(SPRB) pay dividends? If so, how much?
Spruce Biosciences Inc(SPRB) does not pay dividend.
Guru Commentaries on NAS:SPRB
No articles.
Press Release
Articles on Spruce Biosciences Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers